Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 14 Aug 2017 |
| Zealand Pharma A/S publishes a prospectus regarding listing of 4,375,000 new shares on Nasdaq Copenhagen as part of its issue of American Depositary Shares listed on the Nasdaq in the US | 10 Aug 2017 |
| Zealand Pharma A/S publishes prospectus | 10 Aug 2017 |
| Zealand Pharma A/S prices its initial public offering of American Depositary Shares on The Nasdaq Global Select Market in the United States | 9 Aug 2017 |
| Zealand Pharma A/S files final prospectus on a Form F-1 registration statement in connection with the initial public offering of American Depositary Shares in the United States | 9 Aug 2017 |